Edition:
United States

Apricus Biosciences Inc (APRI.OQ)

APRI.OQ on NASDAQ Stock Exchange Capital Market

0.36USD
15 Jun 2018
Change (% chg)

-- (--)
Prev Close
$0.36
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
202,490
52-wk High
$3.34
52-wk Low
$0.25

Chart for

About

Apricus Biosciences, Inc. is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company's drug delivery technology is a permeation enhancer called NexACT. The... (more)

Overall

Beta: 1.47
Market Cap(Mil.): $8.53
Shares Outstanding(Mil.): 23.44
Dividend: --
Yield (%): --

Financials

  APRI.OQ Industry Sector
P/E (TTM): -- 29.97 34.18
EPS (TTM): -0.77 -- --
ROI: -298.91 13.65 13.17
ROE: -413.29 15.43 15.15

BRIEF-Apricus Biosciences Q1 Loss Per Share $0.14

* APRICUS BIOSCIENCES PROVIDES CORPORATE UPDATE AND FIRST QUARTER 2018 FINANCIAL RESULTS

May 03 2018

BRIEF-Apricus Biosciences Says Co Received A Nasdaq Staff Deficiency Letter

* APRICUS BIOSCIENCES SAYS ON APRIL 10, CO RECEIVED A NASDAQ STAFF DEFICIENCY LETTER - SEC FILING Source : https://bit.ly/2JMowAJ Further company coverage: (Reuters.Briefs@thomsonreuters.com)

Apr 16 2018

Apricus mulls options; to sell U.S. rights to Vitaros

Apricus Biosciences Inc said on Monday it was considering options for the company and looking to sell the U.S. rights to its erectile dysfunction cream Vitaros, after the Food and Drug Administration asked it to make a new formula for the product.

Apr 16 2018

UPDATE 2-Apricus mulls options; to sell U.S. rights to Vitaros

* Co has lost $65 mln in market cap since Feb rejection of Vitaros (Adds details on options, background, shares)

Apr 16 2018

BRIEF-Sabby Management LLC Reports 7.68 Pct Passive Stake In Apricus Biosciences

* SABBY MANAGEMENT LLC REPORTS 7.68 PERCENT PASSIVE STAKE IN APRICUS BIOSCIENCES INC AS OF MARCH 28 - SEC FILING Source text : http://bit.ly/2GhQHcF Further company coverage:

Mar 29 2018

BRIEF-Apricus Biosciences Announces Pricing Of $3.55 Mln Public Offering

* APRICUS BIOSCIENCES ANNOUNCES PRICING OF $3.55 MILLION PUBLIC OFFERING

Mar 28 2018

BRIEF-Apricus Biosciences Announces Proposed Public Offering

* APRICUS BIOSCIENCES INC - COMMENCED A PUBLIC OFFERING OF SHARES OF COMMON STOCK AND WARRANTS TO PURCHASE SHARES OF COMMON STOCK Source text for Eikon: Further company coverage:

Mar 27 2018

BRIEF-Sarissa Capital Management Entered Into Warrant Amendment Agreement With Apricus Biosciences

* SARISSA CAPITAL MANAGEMENT LP SAYS ON MARCH 21, ENTERED INTO WARRANT AMENDMENT AGREEMENT WITH APRICUS BIOSCIENCES INC - SEC FILING

Mar 23 2018

BRIEF-Apricus Biosciences Inc Files ‍Prospectus Relates Offering Of Up To 2 Million Shares Of Co's Common Stock By Selling Stockholders - SEC Filing​

* APRICUS BIOSCIENCES INC FILES ‍PROSPECTUS RELATES OFFERING OF UP TO 2 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING​ Source text: (http://bit.ly/2tbNSUG) Further company coverage:

Mar 01 2018

BRIEF-Apricus Biosciences Q4 Loss Per Share $0.16

* APRICUS BIOSCIENCES PROVIDES CORPORATE UPDATE, FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Mar 01 2018

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $36.36 +0.20
GlaxoSmithKline plc (GSK.L) 1,549.14 -6.86
Eli Lilly And Co (LLY.N) $86.88 +0.53
Abbott Laboratories (ABT.N) $62.91 -0.05

Earnings vs. Estimates